Drug Approvals, Data Presentations, Clinical Trials, New Appointments, and Corporate Events - Research Report on Johnson & Johnson, Novo Nordisk, Isis, Keryx, and The Medicines Company

NEW YORK, October 9, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Novo Nordisk A/S (NYSE: NVO), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and The Medicines Company (NASDAQ: MDCO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 27, 2013, Janssen Pharmaceutical K.K., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SOVRIAD (simeprevir sodium), a new direct-acting antiviral agent (DAA), for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection. Commenting on the approval, Bruce Goodwin, President, Janssen Pharmaceutical K.K., stated, "We submitted SOVRIAD for regulatory approval in February of this year before any other country in the world." Goodwin continued, "Data from the four Japanese phase 3 CONCERTO studies that supported the new drug application were presented in June at the Japan Society of Hepatology's 49th Annual Meeting in Tokyo." He added, "SOVRIAD has the potential to offer a new standard treatment option for people infected with chronic hepatitis C in Japan and around the world." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

Novo Nordisk A/S Research Report

On September 27, 2013, Novo Nordisk A/S (Novo Nordisk) announced that phase 3 data from the investigational therapy IDegLira [Tresiba (insulin degludec)/Victoza (liraglutide injection)] were presented at the 49th Annual European Association for the Study of Diabetes (EASD) Congress. Professor Stephen Gough, University of Oxford and Oxford University Hospitals NHS Trust, lead investigator of the study, said, "The efficacy of IDegLira demonstrated by the DUAL™ I data is exciting. It combines the clinical advantages, yet mitigates the principal side effects of insulin degludec and liraglutide. DUAL I shows how patients can achieve an average final HbA1c of 6.4% with no weight gain and a low rate of hypoglycaemia." The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO]

--

Isis Pharmaceuticals, Inc. Research Report

On October 3, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMN_Rx in infants with Type I spinal muscular atrophy (SMA). According to the Company, the Phase 2 study is designed to allow Isis to define the optimal dose for the larger Phase 2/3 study in infants and to provide safety and tolerability data. Isis reported that it earned a $2 million milestone payment from Biogen Idec associated with the advancement of this study, and intends to complete this study and initiate the larger Phase 2/3 pivotal study by early 2014. The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fcfc_ISIS]

--

Keryx Biopharmaceuticals Inc. Research Report

On October 2, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced the appointment of Douglass H. Laidlaw, Ph.D. to the newly created position of Director, Medical Affairs, with oversight of the creation and activities of the Company's Medical Science Liaisons (MSL) team. Ron Bentsur, CEO OF Keryx, commented, "We are excited to be welcoming Dr. Laidlaw to the Company. Dr. Laidlaw brings a proven track record of success in the development and leadership of a dedicated renal MSL team, strategic planning capabilities and a vast network of relationships within the nephrology community. I am confident that he will be an extraordinary asset as we build out our marketing organization." The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX]

--

The Medicines Company Research Report

On October 2, 2013, The Medicines Company announced that it has scheduled a webcast of its upcoming Investor & Analyst Day on Wednesday, October 9, 2013, from 8:30 a.m. to 12:00 p.m. ET. The Medicines Company reported that its management will provide a comprehensive overview of the Company's medical, operational, and financial strategies. The Company also informed that the webcast can be accessed through a link provided at its website. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5a84_MDCO]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner